Last year at the Pharma Compliance Europe 2014 event, Karolina Czernicka-Kuhl, Head of Legal and Compliance, Novo Nordisk, gave the presentation “Developing clear and structured monitoring strategies that minimise risks and optimise compliance success rates.”
Download and learn:
- Why monitoring?
- What should be monitored?
- How to monitor (who should monitor)?
- Benefits and costs
Found this interesting? You might also be interested in our Pharma Compliance Europe 2015 event, taking place 7-8 October in London. Find out more